Copyright © Inderes 2011 - present. All rights reserved.

ALK-Abelló

155

 

DKK

 

-3.49 %

ALK B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

15 following
Compare
-3.49%
-2.58%
-4.97%
-6.23%
+0.45%
+48.61%
-5.55%
+83.65%
+349.28%

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.

Read more
Market cap
34.54B DKK
Turnover
26.57M DKK
Revenue
4.82B
EBIT %
13.81 %
P/E
70.45
Dividend yield-%
-
Coverage
Disclaimer
Financial calendar
19.2
2025

Annual report '24

13.3
2025

General meeting '24

6.5
2025

Interim report Q1'25

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
ALK – Opdatering på de første 9 måneder i 2024 og ny strategisk licensaftale med ARS Pharma
Webcast by
Claus Thestrup

ALK – Opdatering på de første 9 måneder i 2024 og ny strategisk licensaftale med ARS Pharma

Mød og stil spørgsmål til ALK’s EVP og CFO Claus Steensen Sølje og VP & Head of IR Per Plotnikof d. 18. november 2024 kl. 11.15 Ledelsen vil give en gennemgang af den finansielle udvikling i årets tre første kvartaler samt de strategiske aspekter af den netop offentliggjorte licensaftale med ARS Pharma, der giver ALK eksklusive rettigheder til neffy®, der er den første godkendte adrenalin-næsespray til akut behandling af allergiske reaktioner (anafylaksi).

ALK-Abelló
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.